Cargando…

Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer: A case report

As kidney transplant recipients are at increased risk of developing cancer, regular monitoring should be undertaken to monitor the balance between immunosuppression and graft function and to identify malignancy. The present study reports the outcome of the treatment of adenocarcinoma of the lung (T1...

Descripción completa

Detalles Bibliográficos
Autores principales:	ZHAO, QIONG, WANG, YINA, TANG, YEMIN, PENG, LING
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861587/ https://www.ncbi.nlm.nih.gov/pubmed/24348843 http://dx.doi.org/10.3892/ol.2013.1657

Ejemplares similares

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
por: Sun, Sheng-Jie, et al.
Publicado: (2022)

Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations
por: Yao, Shuyang, et al.
Publicado: (2016)

Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib
por: Zhu, Zhouyu, et al.
Publicado: (2016)

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
por: Xia, Pinghui, et al.
Publicado: (2018)

Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report
por: Wang, Tao, et al.
Publicado: (2016)

Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes
por: Wang, Tao, et al.
Publicado: (2016)

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
por: Zhang, Ningning, et al.
Publicado: (2019)

Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone
por: Xu, Yunhua, et al.
Publicado: (2020)

Epidermal Cysts in a Tacrolimus Treated Renal Transplant Recipient
por: Ahn, In Su, et al.
Publicado: (2011)

Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report
por: Zhai, Shu-Sen, et al.
Publicado: (2020)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
por: Xu, Jianping, et al.
Publicado: (2017)

Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
por: Lei, Lei, et al.
Publicado: (2020)

Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers
por: Cheung, Chi Yuen, et al.
Publicado: (2017)

Urinary Epidermal Growth Factor/Creatinine Ratio and Graft Failure in Renal Transplant Recipients: A Prospective Cohort Study
por: Yepes-Calderón, Manuela, et al.
Publicado: (2019)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
por: Zhang, Yun, et al.
Publicado: (2021)

Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer
por: Zhu, Chao, et al.
Publicado: (2019)

Post-transplant small cell carcinoma arising in the native kidney of renal transplant recipient
por: Tang, Wenhao, et al.
Publicado: (2009)

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
por: Feng, Siyang, et al.
Publicado: (2015)

Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma
por: Gemmill, R M, et al.
Publicado: (2005)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells
por: Zhu, Linggang, et al.
Publicado: (2020)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
por: Shen, Yan-Wei, et al.
Publicado: (2016)

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
por: Zhang, Ying, et al.
Publicado: (2015)

Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study
por: Chen, Xiaofeng, et al.
Publicado: (2014)

Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
por: Liang, Jun-Li, et al.
Publicado: (2014)

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
por: Cui, Jiadong, et al.
Publicado: (2018)

The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis
por: Wang, Lulu, et al.
Publicado: (2018)

Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer
por: LIN, Huawei, et al.
Publicado: (2020)

A meta-analysis for the efficacy and safety of icotinib combined with radiotherapy in treating brain metastases of non-small cell lung cancer
por: Zhang, Bo
Publicado: (2023)

Tuberculosis in renal transplant recipients
por: Sundaram, Madhivanan, et al.
Publicado: (2008)

Tuberculosis in renal transplant recipient
por: Kalita, P., et al.
Publicado: (2010)

Adipocytokines in renal transplant recipients
por: Nagy, Kristof, et al.
Publicado: (2016)

Infection in Renal Transplant Recipients
por: Kotton, Camille Nelson, et al.
Publicado: (2010)

Infection in Renal Transplant Recipients
por: Fishman, Jay A., et al.
Publicado: (2008)

Infection in Renal Transplant Recipients
por: Fishman, Jay A., et al.
Publicado: (2005)

Infection in Renal Transplant Recipients
por: Sawinski, Deirdre, et al.
Publicado: (2019)

Hemoptysis in Renal Transplant Recipients
por: Georgakopoulou, Vasiliki Epameinondas, et al.
Publicado: (2021)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
por: Wang, Long, et al.
Publicado: (2021)

Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients
por: Peng, Ling, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0c7kp98bnu8jq4ge4ubtkoe9vs